Компьютерный анализ особенностей регуляции гиперметилированных маркерных генов гепатокарциномы вирусными белками гепатита С

Вирус гепатита С (ВГС) считается фактором риска для возникновения гепатоцеллюлярной карциномы (ГЦК). Известно, что большую роль в молекулярно-генетических механизмах вирус-индуцированного онкогенеза играют эпигенетические изменения. Аберрантное метилирование ДНК служит медиатором эпигенетических изменений, которые тесно связаны с патогенезом ГЦК, и признано биомаркером для его ранней диагностики. С помощью ANDSystem проведены реконструкция и оценка статистической значимости путей потенциальной регуляции вирусными белками ВГС 32 генов человека, гиперметилированных при ГЦК. Среди исследованных генов были как онкосупрессоры, так и проопухолевые гены, идентифицированных по данным 

полногеномного анализа метилирования ДНК. Реконструированы регуляторные пути, включающие белок-белковые взаимодействия, регуляцию экспрессии генов, регуляцию активности, стабильности и транспорта белков. Среди статистически значимых оказались пути регуляции экспрессии. Показано, что восемь из десяти белков ВГС являются участниками данных путей. Белок ВГС NS3 был вовлечен в наибольшее число регуляторных путей. NS3 связан с регуляцией пяти генов-онкосупрессоров, что может свидетельствовать о его центральной роли в патогенезе ГЦК. Анализ реконструированных путей показал, что при ингибировании транскрипционных факторов в результате связывания с вирусными белками, экспрессия ряда онкосупрессоров (WT1, MGMT, SOCS1, P53) подавлялась, тогда как экспрессия других (RASF1, RUNX3, WIF1, DAPK1) активировалась. Таким образом, с помощью реконструкции генных сетей показано, что вирусные белки гепатита С способны влиять не только на статус метилирования генов-онкосупрессоров, но и на их транскрипционную регуляцию. Полученные результаты могут быть использованы при поиске фармакологических мишеней для разработки новых средств против ГЦК, индуцированной ВГС.

1. Benderska N., Schneider-Stock R. Transcription control of DAPK. Apoptosis. 2014;19(2):298-305. DOI 10.1007/s10495-013-0931-6.

2. Bragina E.Y., Tiys E.S., Rudko A.A., Ivanisenko V.A., Freidin M.B. Novel tuberculosis susceptibility candidate genes revealed by the reconstruction and analysis of associative networks. Infect. Genet. Evol. 2016;46:118-123. DOI 10.1016/j.meegid.2016.10.030.

3. Chen J., Li Z., Chen J., Du Y., Song W., Xuan Z., Zhao L., Song G., Song P., Zheng S. Downregulation of MGMT promotes proliferation of intrahepatic cholangiocarcinoma by regulating p21. Clin. Transl. Oncol. 2020;22(3):392-400. DOI 10.1007/s12094-019-02140-9.

4. Chen M., Gan X., Yoshino K., Kitakawa M., Shoji I., Deng L., Hotta H. Hepatitis C virus NS5A protein interacts with lysine methyltransferase SET and MYND domain-containing 3 and induces activator protein 1 activation. Microbiol. Immunol. 2016;60:407-417. DOI 10.1111/1348-0421.12383.

5. Chen P., Meng C., Wang Q., Yang X., Huang Z., Xing X., Lin Y., Liu X., Peng J., Lin Y. Death-associated protein kinase 1 suppresses hepatocellular carcinoma cell migration and invasion by upregulation of DEAD-box helicase 20. Cancer Sci. 2020;111(8):2803-2813. DOI 10.1111/cas.14499.

6. Cheng J., Wei D., Ji Y., Chen L., Yang L., Li G., Wu L., Hou T., Xie L., Ding G., Li H., Li Y. Integrative analysis of DNA methylation and gene expression reveals hepatocellular carcinoma-specific diagnostic biomarkers. Genome Med. 2018;10(1):42. DOI 10.1186/s13073018-0548-z.

7. Choi J., Southworth L.K., Sarin K.Y., Venteicher A.S., Ma W., Chang W., Cheung P., Jun S., Artandi M.K., Shah N., Kim S.K., Artandi S.E. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet. 2008;4(1):e10. DOI 10.1371/journal.pgen.0040010.

8. de Chassey B., Navratil V., Tafforeau L., Hiet M.S., Aublin-Gex A., Agaugué S., Meiffren G., Pradezynski F., Faria B.F., Chantier T., Le Breton M., Pellet J., Davoust N., Mangeot P.E., Chaboud A., Penin F., Jacob Y., Vidalain P.O., Vidal M., André P., RabourdinCombe C., Lotteau V. Hepatitis C virus infection protein network. Mol. Syst. Biol. 2008;4:230. DOI 10.1038/msb.2008.66.

9. Deng Y., Yu B., Cheng Q., Jin J., You H., Ke R., Tang N., Shen Q., Shu H., Yao G., Zhang Z., Qin W. Epigenetic silencing of WIF-1 in hepatocellular carcinomas. J. Cancer Res. Clin. Oncol. 2010; 136(8):1161-1167. DOI 10.1007/s00432-010-0763-5.

10. D’souza S., Lau K.C., Coffin C.S., Patel T.R. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J. Gastroenterol. 2020;26(38):5759-5783. DOI 10.3748/wjg.v26.i38.5759.

11. Feng L., Li J., Yan L.D., Tang J. RASSF1A suppresses proliferation of cervical cancer cells. Asian Pac. J. Cancer Prev. 2014;15(14):59175920. DOI 10.7314/apjcp.2014.15.14.5917.

12. Fernández-Barrena M.G., Arechederra M., Colyn L., Berasain C., Avila M.A. Epigenetics in hepatocellular carcinoma development and therapy: the tip of the iceberg. JHEP Rep. 2020;2(6):100167. DOI 10.1016/j.jhepr.2020.100167.

13. Glotov A.S., Tiys E.S., Vashukova E.S., Pakin V.S., Demenkov P.S., Saik O.V., Ivanisenko T.V., Arzhanova O.N., Mozgovaya E.V., Zainu lina M.S., Kolchanov N.A., Baranov V.S., Ivanisenko V.A. Molecular association of pathogenetic contributors to pre-eclampsia (pre-eclampsia associome). BMC Syst. Biol. 2015:9(Suppl.2):S4.

14. DOI 10.1186/1752-0509-9-S2-S4.

15. Gui Y., Yeganeh M., Ramanathan S., Leblanc C., Pomerleau V., Ferbeyre G., Saucier C., Ilangumaran S. SOCS1 controls liver regeneration by regulating HGF signaling in hepatocytes. J. Hepatol. 2011;55(6): 1300-1308. DOI 10.1016/j.jhep.2011.03.027.

16. Guo N., Chen R., Li Z., Liu Y., Cheng D., Zhou Q., Zhou J., Lin Q. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochim. Biophys. Sin. (Shanghai). 2011; 43(5):354-361. DOI 10.1093/abbs/gmr021.

17. Han Y., Niu J., Wang D., Li Y. Hepatitis C virus protein interaction network analysis based on hepatocellular carcinoma. PLoS One.

18. ;11(4):e0153882. DOI 10.1371/journal.pone.0153882.

19. Hassan M., Ghozlan H., Abdel-Kader O. Activation of c-Jun NH2terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)mediated cell growth. Virology. 2005;333(2):324-336. DOI 10.1016/j.virol.2005.01.008.

20. Hassan M., Selimovic D., Ghozlan H., Abdel-Kader O. Induction of high-molecular-weight (HMW) tumor necrosis factor (TNF) alpha by hepatitis C virus (HCV) non-structural protein 3 (NS3) in liver cells is AP-1 and NF-κB-dependent activation. Cell. Signal. 2007; 19(2):301-311. DOI 10.1016/j.cellsig.2006.07.002.

21. He B., Reguart N., You L., Mazieres J., Xu Z., Lee A.Y., Mikami I., McCormick F., Jablons D.M. Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. Oncogene. 2005;24(18):3054-3058. DOI 10.1038/sj.onc.1208511.

22. Hernandez-Meza G., von Felden J., Gonzalez-Kozlova E.E., GarciaLezana T., Peix J., Portela A., Craig A.J., Sayols S., Schwartz M., Losic B., Mazzaferro V., Esteller M., Llovet J.M., Villanueva A. DNA methylation profiling of human hepatocarcinogenesis. Hepatology. 2021;74(1):183-199. DOI 10.1002/hep.31659.

23. Hoshida Y., Villanueva A., Kobayashi M., Peix J., Chiang D.Y., Camargo A., Gupta S., Moore J., Wrobel M.J., Lerner J., Reich M., Chan J.A., Glickman J.N., Ikeda K., Hashimoto M., Watanabe G., Daidone M.G., Roayaie S., Schwartz M., Thung S., Salvesen H.B., Gabriel S., Mazzaferro V., Bruix J., Friedman S.L., Kumada H., Llovet J.M., Golub T.R. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 2008;359(19):19952004. DOI 10.1056/NEJMoa0804525.

24. Huang L., Li M.X., Wang L., Li B.K., Chen G.H., He L.R., Xu L., Yuan Y.F. Prognostic value of Wnt inhibitory factor-1 expression in hepatocellular carcinoma that is independent of gene methylation. Tumour Biol. 2011;32(1):233-240. DOI 10.1007/s13277-010-0117-6.

25. In der Stroth L., Tharehalli U., Günes C., Lechel A. Telomeres and telomerase in the development of liver cancer. Cancers (Basel).

26. ;12(8):2048. DOI 10.3390/cancers12082048.

27. Ivanisenko N.V., Seyrek K., Kolchanov N.A., Ivanisenko V.A., Lavrik I.N. The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications. Cell Death Discov. 2020;6:101. DOI 10.1038/s41420-020-00331-w.

28. Ivanisenko T.V., Saik O.V., Demenkov P.S., Ivanisenko N.V., Savostianov A.N., Ivanisenko V.A. ANDDigest: a new web-based module of ANDSystem for the search of knowledge in the scientific literature. BMC Bioinformatics. 2020;21(Suppl.11):228. DOI 10.1186/s12859020-03557-8.

29. Ivanisenko V.A., Demenkov P.S., Ivanisenko T.V., Mishchenko E.L., Saik O.V. A new version of the ANDSystem tool for automatic extraction of knowledge from scientific publications with expanded functionality for reconstruction of associative gene networks by considering tissue-specific gene expression. BMC Bioinformatics. 2019;20(Suppl.1):34. DOI 10.1186/s12859-018-2567-6.

30. Ivanisenko V.A., Gaisler E.V., Basov N.V., Rogachev A.D., Cheresiz S.V., Ivanisenko T.V., Demenkov P.S., Mishchenko E.L., Khripko O.P., Khripko Yu.I., Voevoda S.M., Karpenko T.N., Velichko A.J., Voevoda M.I., Kolchanov N.A., Pokrovsky A.G. Plasma metabolomics and gene regulatory networks analysis reveal the role of nonstructural SARS-CoV-2 viral proteins in metabolic dysregulation in COVID-19 patients. Sci. Rep. 2022;12:19977. DOI 10.1038/s41598022-24170-0.

31. Ivanisenko V.A., Saik O.V., Ivanisenko N.V., Tiys E.S., Ivanisenko T.V., Demenkov P.S., Kolchanov N.A. ANDSystem: an Associative Network Discovery System for automated literature mining in the field of biology. BMC Syst. Biol. 2015;9(Suppl.2):S2. DOI 10.1186/17520509-9-S2-S2.

32. Iwai A., Takegami T., Shiozaki T., Miyazaki T. Hepatitis C virus NS3 protein can activate the Notch-signaling pathway through binding to a transcription factor, SRCAP. PLoS One. 2011;6(6):e20718. DOI 10.1371/journal.pone.0020718.

33. Jardin F., Ruminy P., Bastard C., Tilly H. The BCL6 proto-oncogene: a leading role during germinal center development and lymphomagenesis. Pathol. Biol. (Paris). 2007;55(1):73-83. DOI 10.1016/j.patbio.2006.04.001.

34. Jaroszewicz J., Flisiak-Jackiewicz M., Lebensztejn D., Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opin. Investig. Drugs. 2015;24(9):12291239. DOI 10.1517/13543784.2015.1057568.

35. Jiang L.H., Hao Y.L., Zhu J.W. Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clin. Res. Hepatol. Gastroenterol. 2019;43(3):282-291. DOI 10.1016/j.clinre.2018.09.011.

36. Jing W., Peng R., Li X., Lv S., Duan Y., Jiang S. Study on the prognostic values of TTC36 correlated with immune infiltrates and its methylation in hepatocellular carcinoma. J. Immunol. Res. 2022;2022: 7267131. DOI 10.1155/2022/7267131.

37. Kim B.R., Park S.H., Jeong Y.A., Na Y.J., Kim J.L., Jo M.J., Jeong S., Yun H.K., Oh S.C., Lee D.H. RUNX3 enhances TRAIL-induced apoptosis by upregulating DR5 in colorectal cancer. Oncogene. 2019;38:3903-3918. DOI 10.1038/s41388-019-0693-x.

38. Kohsaka S., Wang L., Yachi K., Mahabir R., Narita T., Itoh T., Tanino M., Kimura T., Nishihara H., Tanaka S. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression. Mol. Cancer Ther. 2012;11(6):1289-1299. DOI 10.1158/1535-7163.MCT-11-0801.

39. Konnikova L., Simeone M.C., Kruger M.M., Kotecki M., Cochran B.H. Signal transducer and activator of transcription 3 (STAT3) regulates human telomerase reverse transcriptase (hTERT) expression in human cancer and primary cells. Cancer Res. 2005;65(15):6516-6520. DOI 10.1158/0008-5472.CAN-05-0924.

40. Li B., Li X., Li Y., Guo H., Sun S.Y., He Q.Q., Wang Y., Luo J., Wen J.F., Zheng H., Feng D.Y. The effects of hepatitis C virus nonstructural protein 3 on cell growth mediated by extracellular signalrelated kinase cascades in human hepatocytes in vitro. Int. J. Mol. Med. 2010;26(2):273-279. DOI 10.3892/ijmm_00000462.

41. Lin B., Hong H., Jiang X., Li C., Zhu S., Tang N., Wang X., She F., Chen Y. c-Jun suppresses the expression of WNT inhibitory factor 1 through transcriptional regulation and interaction with DNA methyltransferase 1 in gallbladder cancer. Mol. Med. Rep. 2018;17(6): 8180-8188. DOI 10.3892/mmr.2018.8890.

42. Liu J., Ma Q., Zhang M., Wang X., Zhang D., Li W., Wang F., Wu E. Alterations of TP53 are associated with a poor out-come for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis. Eur. J. Cancer. 2012;48(15):2328-2338. DOI 10.1016/j.ejca.2012.03.001.

43. Llovet J.M., Zucman-Rossi J., Pikarsky E., Sangro B., Schwartz M., Sherman M., Gores G. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 2016;2:16018. DOI 10.1038/nrdp.2016.18.

44. Loeb D.M. WT1 influences apoptosis through transcriptional regulation of Bcl-2 family members. Cell Cycle. 2006;5(12):1249-1253. DOI 10.4161/cc.5.12.2807.

45. Machida K., Cheng K.T., Lai C.K., Jeng K.S., Sung V.M., Lai M.M. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol. 2006;80(14):7199-7207. DOI 10.1128/JVI.00321-06.

46. Machida K., Cheng K.T., Sung V.M., Shimodaira S., Lindsay K.L., Levine A.M., Lai M.Y., Lai M.M. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc. Natl. Acad. Sci. USA. 2004;101(12):4262-4267. DOI 10.1073/pnas.0303971101.

47. Mayo M.W., Wang C.Y., Drouin S.S., Madrid L.V., Marshall A.F., Reed J.C., Weissman B.E., Baldwin A.S. WT1 modulates apoptosis by transcriptionally upregulating the bcl-2 proto-oncogene. EMBO J. 1999;18(14):3990-4003. DOI 10.1093/emboj/18.14.3990.

48. McGlynn K.A., Petrick J.L., El-Serag H.B. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73(Suppl.1):4-13. DOI 10.1002/hep.31288.

49. Mžik M., Chmelařová M., John S., Laco J., Slabý O., Kiss I., Bohovicová L., Palička V., Nekvindová J. Aberrant methylation of tumour suppressor genes WT1, GATA5 and PAX5 in hepatocellular carcinoma. Clin. Chem. Lab. Med. 2016;54(12):1971-1980. DOI 10.1515/cclm-2015-1198.

50. Nault J.C., Ningarhari M., Rebouissou S., Zucman-Rossi J. The role of telomeres and telomerase in cirrhosis and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2019;16(9):544-558. DOI 10.1038/s41575019-0165-3.

51. Neumann O., Kesselmeier M., Geffers R., Pellegrino R., Radlwimmer B., Hoffmann K., Ehemann V., Schemmer P., Schirmacher P., Lorenzo Bermejo J., Longerich T. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology. 2012;56(5):1817-1827. DOI 10.1002/hep.25870.

52. Ni Y., Gu J., Wu J., Xu L., Rui Y. MGMT-mediated neuron apoptosis in injured rat spinal cord. Tissue Cell. 2020;62:101311. DOI 10.1016/j.tice.2019.101311.

53. Nowyhed H.N., Huynh T.R., Blatchley A., Wu R., Thomas G.D., Hedrick C.C. The nuclear receptor Nr4a1 controls CD8 T cell development through transcriptional suppression of Runx3. Sci. Rep. 2015;5:9059. DOI 10.1038/srep09059.

54. Oversoe S.K., Clement M.S., Pedersen M.H., Weber B., Aagaard N.K., Villadsen G.E., Grønbæk H., Hamilton-Dutoit S.J., Sorensen B.S., Kelsen J. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma. Scand. J. Gastroenterol. 2020;55(12):1433-1440. DOI 10.1080/00365521.2020.1837928.

55. Papic N., Maxwell C.I., Delker D.A., Liu S., Heale B.S., Hagedorn C.H. RNA-sequencing analysis of 5′ capped RNAs identifies many new differentially expressed genes in acute hepatitis C virus infection. Viruses. 2012;4:581-612. DOI 10.3390/v4040581.

56. Phan R.T., Dalla-Favera R. The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells. Nature. 2004;432(7017):635639. DOI 10.1038/nature03147.

57. Rabaan A.A., Al-Ahmed S.H., Bazzi A.M., Alfouzan W.A., Alsuliman S.A., Aldrazi F.A., Haque S. Overview of hepatitis C infection, molecular biology, and new treatment. J. Infect. Public Health. 2020;13(5):773-783. DOI 10.1016/j.jiph.2019.11.015.

58. Revill K., Wang T., Lachenmayer A., Kojima K., Harrington A., Li J., Hoshida Y., Llovet J.M., Powers S. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes

59. in hepatocellular carcinoma. Gastroenterology. 2013;145(6):14241435.e1-25. DOI 10.1053/j.gastro.2013.08.055.

60. Saik O.V., Demenkov P.S., Ivanisenko T.V., Bragina E.Y., Freidin M.B., Goncharova I.A., Dosenko V.E., Zolotareva O.I., Hofestaedt R., Lavrik I.N., Rogaev E.I., Ivanisenko V.A. Novel candidate genes important for asthma and hypertension comorbidity revealed from associative gene networks. BMC Med. Genomics. 2018;11(Suppl.1): 15. DOI 10.1186/s12920-018-0331-4.

61. Saik O.V., Ivanisenko T.V., Demenkov P.S., Ivanisenko V.A. Interactome of the hepatitis C virus: literature mining with ANDSystem. Virus Res. 2016;218:40-48. DOI 10.1016/j.virusres.2015.12.003.

62. Sarin K.Y., Cheung P., Gilison D., Lee E., Tennen R.I., Wang E., Artandi M.K., Oro A.E., Artandi S.E. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature. 2005; 436(7053):1048-1052. DOI 10.1038/nature03836.

63. Sawangarun W., Mandasari M., Aida J., Morita K.I., Kayamori K., Ikeda T., Sakamoto K. Loss of Notch1 predisposes oro-esophageal epithelium to tumorigenesis. Exp. Cell Res. 2018;372(2):129-140. DOI 10.1016/j.yexcr.2018.09.019.

64. Schulze K., Imbeaud S., Letouzé E., Alexandrov L.B., Calderaro J., Rebouissou S., Couchy G., Meiller C., Shinde J., Soysouvanh F., Cala tayud A.L., Pinyol R., Pelletier L., Balabaud C., Laurent A., Blanc J.F., Mazzaferro V., Calvo F., Villanueva A., Nault J.C., Bioulac-Sage P., Stratton M.R., Llovet J.M., Zucman-Rossi J. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet. 2015;47(5): 505-511. DOI 10.1038/ng.3252.

65. Sera T., Hiasa Y., Mashiba T., Tokumoto Y., Hirooka M., Konishi I., Matsuura B., Michitaka K., Udaka K., Onji M. Wilms’ tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis. Eur. J. Cancer. 2008;44(4):600-608. DOI 10.1016/j.ejca.2008.01.008.

66. Song Z., Li Z., Han W., Zhu C., Lou N., Li X., Luo G., Peng S., Li G., Zhao Y., Guo Y. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma. Aging (Albany NY). 2020;13(2):1842-1858. DOI 10.18632/aging.103638.

67. Takakura M., Kyo S., Inoue M., Wright W.E., Shay J.W. Function of AP-1 in transcription of the telomerase reverse transcriptase gene (TERT ) in human and mouse cells. Mol. Cell Biol. 2005;25(18): 8037-8043. DOI 10.1128/MCB.25.18.8037-8043.2005.

68. Tan Y., Li Y. HCV core protein promotes hepatocyte proliferation and chemoresistance by inhibiting NR4A1. Biochem. Biophys. Res. Commun. 2015;466(3):592-598. DOI 10.1016/j.bbrc.2015.09.091.

69. Tucci F.A., Broering R., Johansson P., Schlaak J.F., Küppers R. B cells in chronically hepatitis C virus-infected individuals lack a virusinduced mutation signature in the TP53, CTNNB1, and BCL6 genes. J. Virol. 2013;87(5):2956-2962. DOI 10.1128/JVI.03081-12.

70. Xu R.H., Wei W., Krawczyk M., Wang W., Luo H., Flagg K., Yi S., Shi W., Quan Q., Li K., Zheng L., Zhang H., Caughey B.A., Zhao Q., Hou J., Zhang R., Xu Y., Cai H., Li G., Hou R., Zhong Z.,

71. Lin D., Fu X., Zhu J., Duan Y., Yu M., Ying B., Zhang W., Wang J., Zhang E., Zhang C., Li O., Guo R., Carter H., Zhu J.K., Hao X., Zhang K. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. Nat. Mater. 2017; 16(11):1155-1161. DOI 10.1038/nmat4997.

72. Yang C., Zhang Y., Wang J., Li L., Wang L., Hu M., Xu M., Long Y., Rong R., Zhu T. A novel cyclic helix B peptide inhibits dendritic cell maturation during amelioration of acute kidney graft rejection through Jak-2/STAT3/SOCS1. Cell Death Dis. 2015;6(11):e1993. DOI 10.1038/cddis.2015.338.

73. Ye S., Zhao X.Y., Hu X.G., Li T., Xu Q.R., Yang H.M., Huang D.S., Yang L. TP53 and RET may serve as biomarkers of prognostic evaluat ion and targeted therapy in hepatocellular carcinoma. Oncol. Rep. 2017;37(4):2215-2226. DOI 10.3892/or.2017.5494.

74. Zhang C., Li J., Huang T., Duan S., Dai D., Jiang D., Sui X., Li D., Chen Y., Ding F., Huang C., Chen G., Wang K. Meta-analysis of DNA methylation biomarkers in hepatocellular carcinoma. Oncotarget. 2016;7(49):81255-81267. DOI 10.18632/oncotarget.13221.

75. Zhang H., Weng X., Ye J., He L., Zhou D., Liu Y. Promoter hypermethylation of TERT is associated with hepatocellular carcinoma in the Han Chinese population. Clin. Res. Hepatol. Gastroenterol. 2015;39(5):600-609. DOI 10.1016/j.clinre.2015.01.002.

76. Zhu Z., Tran H., Mathahs M.M., Moninger T.O., Schmidt W.N. HCV induces telomerase reverse transcriptase, increases its catalytic activity, and promotes caspase degradation in infected human hepatocytes. PLoS One. 2017;12(1):e0166853. DOI 10.1371/journal.pone.0166853.

77. Zhu Z., Wilson A.T., Gopalakrishna K., Brown K.E., Luxon B.A., Schmidt W.N. Hepatitis C virus core protein enhances Telomer ase activity in Huh7 cells. J. Med. Virol. 2010;82(2):239-248. DOI 10.1002/jmv.21644.

78. Zong C., Qin D., Yu C., Gao P., Chen J., Lu S., Zhang Y., Liu Y., Yang Y., Pu Z., Li X., Fu Y., Guan Q., Wang X. The stress-response molecule NR4A1 resists ROS-induced pancreatic β-cells apoptosis via WT1. Cell Signal. 2017;35:129-139. DOI 10.1016/j.cellsig.2017.03.012.

79. Zucman-Rossi J., Villanueva A., Nault J.C., Llovet J.M. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149(5):1226-1239.e4. DOI 10.1053/j.gastro.2015.05.061.